Penn Medicine Develops Potent mRNA Vaccine Against Lethal H5N1 Virus

Experimental mRNA vaccine proves highly effective against H5N1 in animal studies, offering hope for rapid pandemic response.

Researchers from the Perelman School of Medicine at the University of Pennsylvania have developed an experimental mRNA vaccine against avian influenza virus H5N1. The vaccine is highly effective in preventing severe illness and death in preclinical models and could help manage the current H5N1 outbreaks in birds and cattle in the United States and prevent its transmission to humans.

This research was recently published in Nature Communications.

Advantages of mRNA Technology in Vaccine Development

Scott Hensley, PhD, a professor of Microbiology at the Perelman School of Medicine, highlighted the flexibility of mRNA technology in vaccine development. “The mRNA technology allows us to be much more agile in developing vaccines; we can start creating an mRNA vaccine within hours of sequencing a new viral strain with pandemic potential,” he explained.

“During previous influenza pandemics, like the 2009 H1N1 pandemic, vaccines were difficult to manufacture and did not become available until after the initial pandemic waves subsided.”

Hensley’s laboratory worked on this study in collaboration with the laboratory of mRNA vaccine pioneer and Nobel Prize winner Drew Weissman, MD, PhD.

“Before 2020, experts thought the influenza virus posed the greatest risk of causing a pandemic, and we had limited options for creating a vaccine if that had happened,” said Weissman. “COVID-19 showed us the power of mRNA-based vaccines as tool to protect humans from emerging viruses quickly, and we are better prepared now to respond to a variety of viruses with pandemic potential, including influenza”

Traditional vs. mRNA Vaccine Production

Most influenza vaccines are egg-based, where experts inject fertilized chicken eggs with what they predict will be the dominant viral strain, let it replicate, and then inactivate the virus to use in the flu shots distributed globally. However, viruses must first be adapted to replicate in fertilized eggs before these conventional vaccines can be produced, which can take up to six months, presenting potential problems for quickly producing vaccine when it’s needed most during the first few months of a pandemic. mRNA vaccines are easily and quickly adapted to protect against different strains of influenza viruses, and don’t require eggs for their development.

Study Findings and Vaccine Efficacy

The Penn researchers developed an mRNA vaccine targeting a specific subtype of the H5N1 virus that is circulating widely in birds and cattle. While it rarely infects humans, some fear that the virus may evolve and cause a human pandemic. The researchers found that the vaccine elicited a strong antibody and T-cell response in mice and ferrets. What’s more, the animals maintained high levels of antibodies even a year after vaccination. Additionally, the researchers found that vaccinated animals who were subsequently infected with H5N1 cleared the virus more rapidly and displayed fewer symptoms than unvaccinated controls. The researchers also note that all of the vaccinated animals survived following H5N1 infection, whereas all the unvaccinated animals died.

Finally, the researchers compared the mRNA vaccine response in mice to their response to a traditional egg-based vaccine and found that the mRNA vaccine was just as effective; both vaccines elicited strong antibody responses, regardless of prior seasonal flu exposures.

Reference: “Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus” by Colleen Furey, Gabrielle Scher, Naiqing Ye, Lisa Kercher, Jennifer DeBeauchamp, Jeri Carol Crumpton, Trushar Jeevan, Christopher Patton, John Franks, Adam Rubrum, Mohamad-Gabriel Alameh, Steven H. Y. Fan, Anthony T. Phan, Christopher A. Hunter, Richard J. Webby, Drew Weissman and Scott E. Hensley, 23 May 2024, Nature Communications.
DOI: 10.1038/s41467-024-48555-z

The Hunter Laboratory at the University of Pennsylvania School of Veterinary Medicine, the Webby Lab at St. Jude, and Steven Fan at Acuitas also contributed to this research.

This research was funded by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, and the Department of Health and Human Services (75N93021C00015, 75N93021C00016, R01AI08686, and R01AI126899).